Share chart Avadel Pharmaceuticals plc
Extended chart
Simple chart
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc работает как биофармацевтическая компания в США. Его ведущим продуктом-кандидатом является LUMRYZ, состав оксибата натрия, который находится в фазе 3 клинических испытаний для лечения чрезмерной дневной сонливости или катаплексии у взрослых с нарколепсией. Компания, ранее известная как Flamel Technologies SA, сменила название на Avadel Pharmaceuticals plc в январе 2017 года. Avadel Pharmaceuticals plc была зарегистрирована в 2015 году, ее штаб-квартира находится в Дублине, Ирландия.IPO date | 1996-06-07 |
---|---|
ISIN | US05337M1045 |
Industry | Pharmaceuticals |
Sector | Health Care |
Валюта | usd |
Валюта отчета | usd |
Сайт | https://www.avadel.com |
Цена ао | 8.39 |
Change price per day: | 0% (8.39) |
---|---|
Change price per week: | +6.07% (7.91) |
Change price per month: | -5.84% (8.91) |
Change price per 3 month: | -19.25% (10.39) |
Change price per half year: | -39.25% (13.81) |
Change price per year: | -47.3% (15.92) |
Change price per 3 year: | +16.2% (7.22) |
Change price per 5 year: | +20.72% (6.95) |
Change price per 10 year: | 0% (8.39) |
Change price per year to date: | -18.62% (10.31) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
ETF | Share, % | Profitability for 1 year, % | Dividends, % |
---|---|---|---|
iShares Neuroscience and Healthcare ETF | 2.25833 | 19.72 | 0.03 |
Future Tech ETF | 0.12494 | 426.34 | 0.8416 |
Principal Healthcare Innovators ETF | 0.12494 | 618.5 | 0.8416 |
![]() |
0.09093 | 38.04 | 0.6026 |
iShares Morningstar Small-Cap Growth ETF | 0.0533 | 33.63 | 0.72598 |
iShares Morningstar Small-Cap Growth ETF | 0.0533 | 587.89 | 0.72598 |
iShares Morningstar Small-Cap ETF | 0.0271 | 30.1 | 1.60498 |
iShares Morningstar Small-Cap ETF | 0.0271 | 391.25 | 1.60498 |
iShares Russell 3000 ETF | 0.00222 | 24.83 | 1.43482 |
0.31 | 241.14 | 0.93 |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Mr. Gregory J. Divis Jr. | CEO & Director | 753.69k | 1967 (58 years) |
Mr. Thomas S. McHugh | Senior VP, Principal Financial and Accounting Officer & CFO | 526k | 1965 (60 years) |
Mr. Richard J. Kim | Chief Commercial Officer | 548.44k | 1969 (56 years) |
Mr. Jerad G. Seurer | General Counsel & Company Secretary | N/A | 1973 (52 years) |
Mr. Gregory J. Davis | VP of Corporate and Business Development | N/A | 1965 (60 years) |
Mr. Mark W. Elrod | Vice President of Sales | N/A | |
Ms. Angie Woods | Vice President of People & Culture | N/A | |
Dr. Jordan S. Dubow M.D. | Consultant | 727.93k | 1978 (47 years) |
Dr. Jason M. Vaughn | Senior Vice President of Technical Operations | N/A | |
Ms. Jennifer Gudeman PharmD | Senior Vice President of Medical & Clinical Affairs | N/A |
Address: Ireland, Dublin, 10 Earlsfort Terrace - open in Google maps, open in Yandex maps
Website: https://www.avadel.com
Website: https://www.avadel.com